Last checked at 14 Dec 2020 08:01
14 December 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Holding(s) in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has been notified that Mr. David Farrier holds a total of 12,540,385 Ordinary Shares, representing 6.92% of the total issued share capital of the Company as enlarged by the placing announced on 9 December 2020.
Enquiries:
N4 Pharma plc | |
Nigel Theobald, CEO | Via IFC Advisory |
Luke Cairns, Executive Director | |
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Joint Broker | |
Matthew Johnson/Caroline Rowe (Corporate Finance) | |
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | |
Turner Pope Investments (TPI) Limited | Tel: +44(0)20 3657 0050 |
Joint Broker | |
Andy Thacker | |
IFC Advisory Ltd | Tel: +44(0)20 3934 6630 |
Financial PR | |
Graham Herring | |
Zach Cohen | |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.